Studies
Swipe or Scroll to see our currently enrolling studies.
Open Label Treatment for Depression
Adams Clinical sponsors an open-label study for those who are experiencing depression and want to participate in a clinical trial. For each 6 week treatment cycle, Adams Clinical monitors participants' responses to an FDA- approved antidepressant as part of the TRAIT-MDD-107 protocol.
Mild Alzheimer's Disease
Adams Clinical is testing ABBV-552 in individuals who are experiencing mild Alzheimer's disease. ABBV-552 is an oral drug that modulates synaptic vesicle glycoprotein 2a (SV2A) and is being tested in the M23-515 protocol. This protocol is also called the AbroAD study.
Early Symptomatic Alzheimer's Disease
Adams Clinical is testing remternetug in individuals who are experiencing early symptomatic Alzheimer's disease. Remtenretug is a monoclonal antibody directed at the pyroglutamate forms of amyloid beta that is aggregated in amyloid plaques (N3pG4 AB), and it is being tested in the J1G-MC-LAKC protocol. This protocol is also called TRAILRUNNER-ALZ-1.
2nd-Line Adjunctive Treatment for Depression
Adams Clinical is testing ulotaront in individuals who are experiencing depression and have failed to respond to at least one antidepressant. Ulotaront is a TAAR1 agonist and is being tested in the 382-201-00001 protocol.
-
‹
-
›